ReShape Lifesciences Inc. (NASDAQ: RSLS) shares saw a sharp increase during the last trading session, rising more than 35% to close at $3.11. The significant upswing followed an announcement of the establishment of an exclusive U.S. distribution deal with Recon Supply, a fast growing distributor specializing in veterans’ healthcare.
Expanding Veterans’ and Military Health Care Access
In the healthcare systems of the Department of Defense (DoD) and Veterans Administration (VA), Recon Supply will market ReShape’s portfolio of cutting-edge medical technology. That also includes the STIMEL-03 neuromuscular rehabilitation device and the Lap-Band 2.0 FLEX weight reduction system. Over 18 million active-duty military members and veterans are anticipated to benefit from the agreement by receiving RSLS’ FDA-approved, scientifically proven goods.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Creative Remedies for Challenging Medical Issues
The STIMEL-03 system is a cutting-edge neurorehabilitation platform designed to help patients recover from strokes, injuries, and surgeries. It has personalized electrical stimulation and real-time EMG biofeedback. A cutting-edge, minimally invasive treatment for obesity, a problem that disproportionately affects veterans, is provided with the Lap-Band 2.0 FLEX. Both products are engineered to meet the unique and often complex medical needs of military-affiliated patients.
Nationwide Reach Through Established Federal Channels
Recon Supply brings an extensive and growing presence across the VA and DoD systems, with access supported by federal contracts including the Distribution and Pricing Agreement (DAPA), Federal Supply Schedule (FSS), and Electronic Catalog (ECAT). Since its relaunch in 2022, the company has achieved over 113% year-over-year growth and now serves 102 VA Medical Centers nationwide, operated primarily by veterans and their families.
An Important Advancement
This collaboration represents a significant milestone for ReShape Lifesciences in the company’s continuous mission to provide access to transformative medical technologies. RSLS is in a position to significantly influence the standard of treatment accessible to veterans because of improved access to essential healthcare networks.
